A Randomized Phase 2/3 Study Comparing BMS-986504 in Combination with Nab-paclitaxel and Gemcitabine versus Placebo in Combination with Nab-paclitaxel and Gemcitabine in Participants with Untreated Metastatic Pancreatic Ductal Adenocarcinoma Harboring

Brief description of study

CA240-0030 A Randomized, Phase 2/3 Study Comparing BMS-986504 in Combination with Nab-paclitaxel and Gemcitabine versus Placebo in Combination with Nab-paclitaxel and Gemcitabine in Participants with Untreated Metastatic Pancreatic Ductal Adenocarcinoma Harboring Homozygous MTAP Deletion


Clinical Study Identifier: s25-00693
ClinicalTrials.gov Identifier: NCT07076121
Principal Investigator: Kristen Spencer.
Other Investigators: Caitlin Elizabeth Ordonez Ferri, Kelly C O'Sullivan, Michael Shusterman, Daniel J Becker, Tiffany S Wang, Marta Wioleta Wronska, Lourdes Gaddi, Jennifer Chuy, Allie Nussbaum, Monica Rivera, Shushma Upadhayay, Keriann M Scavone, Zefie Kanos, Nina Beri, Paul E. Oberstein, Anastasiya Apanasyuk, Ilana Zacharia, Rafael Winograd, Emmanuel Andres Pelayo, Shun Yu, Alexander A Hindenburg.


If you are registered as a volunteer, please log in to contact the study team/express interest in this study.

Contact the research team to learn more about this study.

By clicking "Contact Research Team", your contact information will be sent securely to the research staff associated with the study. You will also receive a copy of this email in your inbox, as well as other notifications to determine your participation status in the study.